Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

Understanding Serge Belanger’s Investment Rating: Key Influencing Factors

Oppenheimer Remains a Buy on Cytokinetics (CYTK)

Buy Rating Affirmed on Cytokinetics Amid Promising Aficamten Clinical Results

Buy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial Results

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session

Cytokinetics (CYTK) Receives a Hold from Bank of America Securities

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Top Pictet Fund Manager Sees Biotech Stocks Joining AI-Euphoria

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

2 Incredible Growth Stocks to Buy Right Now

Truist Financial Gives a Buy Rating to Cytokinetics (CYTK)

Cytokinetics to Participate in March Investor Conferences